Your shopping cart is currently empty

Abd110 (compound 42i), a Lenalidomide-based PROTAC ATR kinase degrader, selectively reduces levels of ATR and phospho-ATR while not impacting the related kinases ATM and DNA-PKcs [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Abd110 (compound 42i), a Lenalidomide-based PROTAC ATR kinase degrader, selectively reduces levels of ATR and phospho-ATR while not impacting the related kinases ATM and DNA-PKcs [1]. |
| In vitro | Abd110 (compound 42i; 0.5-2 μM; 24 h) selectively degrades ATR by relying on the E3 ubiquitin ligase component cereblon, while not affecting the related kinases ATM and DNA-PKcs [1]. In a cell viability assay using the MIA PaCa-2 cell line at concentrations of 0.5 μM, 1 μM, and 2 μM for 24 hours, Abd110 resulted in decreased levels of ATR and p-ATR without impacting other checkpoint kinases. |
| Molecular Weight | 790.89 |
| Formula | C41H42N8O7S |
| Cas No. | 3021581-79-0 |
| Smiles | O=C(NC=1C=CC=CC1)C=2N=C(C=NC2N)C3=CC=C(C=C3)S(=O)(=O)NCCCCCC(=O)NCCCC#CC4=CC=CC=5C(=O)N(CC45)C6C(=O)NC(=O)CC6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.